Literature DB >> 21859049

Incremental health care utilization and expenditures for chronic rhinosinusitis in the United States.

Neil Bhattacharyya1.   

Abstract

OBJECTIVES: I determined incremental increases in health care expenditures and utilization associated with chronic rhinosinusitis (CRS).
METHODS: Patients with a reported diagnosis of CRS were extracted from the 2007 Medical Expenditure Panel Survey medical conditions file and linked to the consolidated expenditures file. The patients with CRS were then compared to patients without CRS to determine differences in health care utilization (office visits,emergency facility visits, and prescriptions filled), as well as differences in health care expenditures (total health care costs, office visit costs, prescription medication costs, and self-expenditures) by use of demographically adjusted and comorbidity-adjusted multivariate models.
RESULTS: An estimated 11.1+/-0.48 million adult patients reported having CRS in 2007 (4.9%+/-0.2% of the US population). The additional incremental health care utilizations associated with CRS relative to patients without CRS for office visits, emergency facility visits, and number of prescriptions filled were 3.45+/-0.42, 0.09+/-0.03, and 5.5+/-0.8, respectively (all p<or=0.001). Similarly, additional health care expenditures associated with CRS for total health care expenses, office-based expenditures, prescription expenditures, and self-expenditures were $772+/-$300, $346+/-$130, $397+/-$88, and $90+/-$24, respectively (all p<or=0.01).
CONCLUSIONS: Chronic rhinosinusitis is associated with a substantial incremental increase in health care utilization and expenditures due to increases in office-based and prescription expenditures. The national health care costs of CRS remain very high, at an estimated $8.6 billion per year.

Entities:  

Mesh:

Year:  2011        PMID: 21859049     DOI: 10.1177/000348941112000701

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  93 in total

Review 1.  Surgical versus medical interventions in CRS and nasal polyps: comparative evidence between medical and surgical efficacy.

Authors:  Osama Dessouky; Claire Hopkins
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

2.  Bactericidal antibiotics promote reactive oxygen species formation and inflammation in human sinonasal epithelial cells.

Authors:  Michael A Kohanski; Anuj Tharakan; Andrew P Lane; Murugappan Ramanathan
Journal:  Int Forum Allergy Rhinol       Date:  2015-12-01       Impact factor: 3.858

3.  Single Nucleotide Polymorphisms in Chemosensory Pathway Genes GNB3, TAS2R19, and TAS2R38 Are Associated with Chronic Rhinosinusitis.

Authors:  Phillip R Purnell; Benjamin L Addicks; Habib G Zalzal; Scott Shapiro; Sijin Wen; Hassan H Ramadan; Vincent Setola; David P Siderovski
Journal:  Int Arch Allergy Immunol       Date:  2019-05-28       Impact factor: 2.749

Review 4.  Immunopathology of chronic rhinosinusitis.

Authors:  Atsushi Kato
Journal:  Allergol Int       Date:  2015-02-09       Impact factor: 5.836

5.  The personal financial burden of chronic rhinosinusitis: A Canadian perspective.

Authors:  Jonathan Yip; Allan D Vescan; Ian J Witterick; Eric Monteiro
Journal:  Am J Rhinol Allergy       Date:  2017-07-01       Impact factor: 2.467

Review 6.  Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis.

Authors:  Brittany E Howard; Devyani Lal
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

7.  Long-term outcome of once daily nasal irrigation for the treatment of pediatric chronic rhinosinusitis.

Authors:  Vinh Pham; Kevin Sykes; Julie Wei
Journal:  Laryngoscope       Date:  2013-12-06       Impact factor: 3.325

8.  RNA sequencing and pathway analysis identify tumor necrosis factor alpha driven small proline-rich protein dysregulation in chronic rhinosinusitis.

Authors:  Vijay R Ramakrishnan; Joseph R Gonzalez; Sarah E Cooper; Henry P Barham; Catherine B Anderson; Eric D Larson; Carlyne D Cool; John D Diller; Kenneth Jones; Sue C Kinnamon
Journal:  Am J Rhinol Allergy       Date:  2017-09-01       Impact factor: 2.467

Review 9.  Pharmacological Management of Chronic Rhinosinusitis: Current and Evolving Treatments.

Authors:  Daniel M Beswick; Stacey T Gray; Timothy L Smith
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

10.  In vitro effects of anthocyanidins on sinonasal epithelial nitric oxide production and bacterial physiology.

Authors:  Benjamin M Hariri; Sakeena J Payne; Bei Chen; Corrine Mansfield; Laurel J Doghramji; Nithin D Adappa; James N Palmer; David W Kennedy; Masha Y Niv; Robert J Lee
Journal:  Am J Rhinol Allergy       Date:  2016-07       Impact factor: 2.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.